Most importantly, GLP-1 analogs do not carry the risk of neuroglycopenia in patients with Alzheimer’s disease, which could potentially lead to cognitive decline in this group of patients [193]. This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.